GH · NASDAQ · Medical - Diagnostics & Research

Guardant Health

Blood and tissue cancer tests spanning screening, monitoring, and treatment selection.

$161.50
After-hours close−0.05 (−0.03%)
At close$161.55(−4.14%)

Breakdown13F · Form 4

Institutions 116.38%Insiders 1.87%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 134.20M · Float 128.82M · 96.0% free float

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
Wellington Group Holdings LLP10.13M8.23%13GNov 8, 2024
BlackRock, Inc.7.62M5.68%13FAug 7, 2026
T. Rowe Price Associates, Inc.7.04M5.40%13GMay 15, 2026
Cadian Capital Management GP, LLC7.01M5.70%13GNov 13, 2024
Price T Rowe Associates Inc /MD/6.51M4.85%13FAug 14, 2026

Institutions13F, as of Jun 30, 2026

622 holders · 156.17M shares · 156 new positions · 353 increased · 185 reduced · 48 closed

HolderShares% outstandingChg q/qFiled
BlackRock, Inc.7.62M5.68%−3.93MAug 7, 2026
Price T Rowe Associates Inc /MD/6.51M4.85%−508.7KAug 14, 2026
Vanguard Capital Management LLC5.76M4.29%+131.7KAug 13, 2026
FMR LLC5.49M4.09%+1.37MAug 13, 2026
Vanguard Portfolio Management LLC5.45M4.06%−392.2KAug 13, 2026
Invesco Ltd.4.43M3.30%−516.7KAug 14, 2026
Goldman Sachs Group Inc3.78M2.81%−659.9KAug 14, 2026
Two Sigma Investments, LP3.72M2.77%−510.2KAug 14, 2026

Beneficial owners13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Wellington Group Holdings LLPincl. Wellington Management Company LLP, Wellington Management Group LLP +1 more8.23%10.13M13GNov 8, 2024
BlackRock, Inc.7.50%9.29M13GApr 17, 2025
Cadian Capital Management GP, LLCincl. Cadian Capital Management, LP, Eric Bannasch5.70%7.01M13GNov 13, 2024
T. Rowe Price Associates, Inc.5.40%7.04M13GMay 15, 2026
Deep Track Biotechnology Master Fund, Ltd.incl. David Kroin, Deep Track Capital, LP5.35%6.58MOct 7, 2024
Vanguard Capital Management5.02%6.59M13GApr 30, 2026

InsidersForm 4

InsiderRoleShares% outstandingFiled
Helmy Eltoukhydirector, officer: Co-Chief Executive Officer1.94M1.45%Aug 27, 2026
Darya Chudovaofficer: Chief Technology Officer130.5K0.10%Jul 2, 2026
Craig Eagleofficer: Chief Medical Officer68.1K0.05%Apr 2, 2026
Chris Freemanofficer: Chief Commercial Officer65.4K0.05%Aug 11, 2026
Michael Brian Bellofficer: Chief Financial Officer50.5K0.04%Jul 2, 2026
Kumud Kaliaofficer: Chief Information Officer42.4K0.03%Jul 2, 2026
John G. Saiaofficer: Chief Legal Officer39.0K0.03%Aug 12, 2026
AmirAli Talasazdirector, officer: Co-Chief Executive Officer37.5K0.03%Aug 24, 2026
Vijaya Gaddedirector28.5K0.02%Jun 22, 2026
Terilyn J. Monroeofficer: Chief People Officer23.0K0.02%Aug 13, 2026

9 ten-percent owners hold 39.66M shares by Form 4, outside the officers-and-directors figure above · 10 people have not refiled in the last 18 months (304.2K shares), so they are not in the figure above

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Aug 21, 2026
AmirAli Talasazdirector, officer: Co-Chief Executive Officer
Sale · 3 lots37,500$169.1637,500
Aug 17, 2026
Musa Tariqdirector
Sale116$156.4511,316
Aug 12, 2026
Terilyn J. Monroeofficer: Chief People Officer
Sale · 5 lots46,300$165.1222,979
Aug 10, 2026
Chris Freemanofficer: Chief Commercial Officer
Sale · 4 lots63,605$169.5865,374
Aug 5, 2026
Medina Manuel Hidalgodirector
Sale · 2 lots1,700$164.244,556
Aug 4, 2026
Ian T. Clarkdirector
Sale · 2 lots14,180$158.922,975
Jul 16, 2026
Musa Tariqdirector
Sale116$163.2911,182
Jun 29, 2026
AmirAli Talasazdirector, officer: Co-Chief Executive Officer
Sale · 4 lots143,028$151.541,881,336
Jun 26, 2026
AmirAli Talasazdirector, officer: Co-Chief Executive Officer
Sale · 2 lots116,972$150.791,881,336
Jun 15, 2026
Kumud Kaliaofficer: Chief Information Officer
Sale600$131.0840,814

CongressHouse and Senate disclosures

Not reported.